CAV1 and systemic sclerosis: Increased levels of TGF‐β and TNF‐α in both blood and tissues of SSc patients contribute to the reduced expression of Cav‐1 in monocytes, whereas treatment with CSD peptides restores Cav‐1 levels in these cells, suggesting that CSD peptides may help alleviate SSc‐associated ILD [105].